Gene therapy reverses symptoms of rare neurological disease in animal models microbiologystudy

Gene therapy reverses symptoms of rare neurological disease in animal models
Credit: Molecular Therapy (2025). DOI: 10.1016/j.ymthe.2025.02.046

A recent study led by the UAB demonstrates the potential of gene therapy to restore motor capacity in an ultra-rare disease, megalencephalic leukoencephalopathy with subcortical cysts (MLC), even when treatment begins after symptom onset.

MLC is a rare childhood neurological disorder that primarily affects the brain’s white matter. It is characterized by macrocephaly, impaired motor coordination, and epilepsy, among other symptoms. More than 75% of diagnosed cases are caused by mutations in the MLC1 gene, which encodes a protein located in the membrane of a type of brain cell called astrocyte. This protein plays a key role in regulating water and ion balance in the brain, but its exact function is still not well understood.

In this research, a team led by Assumpció Bosch from the Department of Biochemistry and Molecular Biology and the Institut de Neurociències of the UAB (INc-UAB) administered a viral vector carrying a healthy copy of the MLC1 gene to an animal model of the disease in order to restore normal protein activity.

The results confirmed the effectiveness of the treatment, as gene expression was maintained in the brain for a year, normalizing physiologic brain alterations and reversing motor impairments in treated mice.

The study, published in Molecular Therapy, represents “a significant breakthrough, as it suggests that gene therapy could be effective even in advanced stages of the disease,” explains Alejandro Brao, researcher at the Department of Biochemistry and Molecular Biology and INc-UAB, and first author of the article.

Gene therapy reverses symptoms of rare neurological disease in animal models
The research team that conducted the study. From left to right, Miguel Chillón, Jorge Lunar, Assumpció Bosch, Ángela Sánchez, Javier del Rey, Irina Rodríguez and Alejandro Brao. Credit: Autonomous University of Barcelona

“Our next steps will focus on identifying the most suitable gene therapy vector for clinical application, determining the minimum effective dose, and conducting biosafety and biodistribution studies in larger animal models,” added Assumpció Bosch, coordinator of the study.

These research findings have the potential to open new therapeutic avenues for MLC patients while also showcasing the promise of gene therapy in treating rare neurological diseases by restoring the expression of affected genes.

More information:
Alejandro Brao et al, Gene therapy rescues brain edema and motor function in a mouse model of megalencephalic leukoencephalopathy with subcortical cysts, Molecular Therapy (2025). DOI: 10.1016/j.ymthe.2025.02.046

Provided by
Autonomous University of Barcelona


Citation:
Gene therapy reverses symptoms of rare neurological disease in animal models (2025, March 31)
retrieved 31 March 2025
from https://medicalxpress.com/news/2025-03-gene-therapy-reverses-symptoms-rare.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top